Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853648 | 1.00 | TSHR (0.36) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL11156490 | 0.95 | POLB (0.37) | MAPTKDM4EHDAC1HDAC6ALDH1A1 | |
| SCHEMBL11149555 | 0.89 | HDAC1 (0.36) | TSHRHDAC1HDAC6ALDH1A1HSD17B10 | |
| SCHEMBL14035562 | 0.88 | CNR2 (0.45) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL30192734 | 0.88 | CNR2 (0.45) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL11152319 | 0.87 | HDAC1 (0.36) | HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11162250 | 0.86 | ALDH1A1 (0.42) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL112752 | 0.86 | KCNQ3 (0.37) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL11147503 | 0.85 | ALDH1A1 (0.42) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL11150640 | 0.85 | HDAC1 (0.37) | TSHRSMN1; SMN2HDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0032620-B2 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1987-02-04 | — | — | EP | claimed |
| EP-0032620-B1 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1984-05-30 | — | — | EP | claimed |
| US-4398035-A | INTERMEDIATE FOR FLURBIPROFEN | THE UPJOHN COMPANY (US) | 1983-08-09 | — | — | US | claimed |
| EP-0032620-A1 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1981-07-29 | — | — | EP | claimed |
| JP-57016830-A | — | — | None | — | — | JP | disclosed |
| CN-117645535-A | Flurbiprofen intermediate and preparation method of flurbiprofen | 河北鼎泰制药有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2021042411-A1 | AKR1C3 INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT OF SAME, PREPARATION METHOD FOR SAME, AND USES THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110590548-B | AKR1C3 inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-09-08 | — | — | CN | disclosed |
| CN-110590548-A | AKR1C3 inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-20 | — | — | CN | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-0100120-B1 | IMPROVEMENT IN THE PROCESS FOR PREPARING BIARYL COMPOUNDS VIA COUPLING OF AN ARYLAMINE WITH AN ARENE | Nobel Chemicals AB (SE) | 1988-02-03 | — | — | EP | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| EP-0032620-B1 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
| US-4398035-A | INTERMEDIATE FOR FLURBIPROFEN | THE UPJOHN COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
| US-4324904-A | COMPOUND USEFUL IN MAKING FLURBIPROFEN | THE UPJOHN COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
| JP-S5716830-A | PREPARATION OF BIPHENYL DERIVATIVE | SAGAMI CHEM RES CENTER | 1982-01-28 | — | — | JP | disclosed |
| EP-0032620-A1 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4266069-A | Processes for the preparation of hydratropic acids and esters | THE UPJOHN COMPANY (US) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | TSHR 4376/4885MAPT 3703/4885KDM4E 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.